A breakthrough of the year, the value of academic research, and more...
In this issue, get your finger on the pulse of a potential gene therapy for heart failure, read about the HIV drug that was named Science's 2024 Breakthrough of the Year, and learn why "mirror life" should probably stay a hypothetical.
|
|
|
Research fills critical knowledge gaps in medical science. It leads to new treatments and technologies that improve public health. It also supports jobs, fuels innovation and entrepreneurship, and provides training for tomorrow’s scientists.
|
|
|
AWARDS, RECOGNITION, & OTHER NOTES |
- There are no immediate events to promote, so enjoy the holiday season. But do keep an eye on future events in 2025, including:
|
|
|
|
Research in the Sundquist lab laid the foundations for the development of lenacapavir. Developed by Gilead Sciences, lenacapavir provides protection for half a year instead of one day and has performed extremely well in clinical trials.
|
|
|
| The therapy dramatically improves survival in a large animal model of heart failure, via what a paper describing the results calls “an unprecedented recovery of cardiac function.”
|
|
|
|
Synthetic organisms, mirror-reversed from natural life at the molecular level, are currently a hypothetical, but advances in technology may make them possible within decades. Such "mirror life" could aid drug development, but could also pose unpredictable risks to health and the environment.
|
|
|
|
Mechanical engineering student Sebastion Jenson uses Protospace's 3D printing and scanning equipment to help validate and test materials and medical devices for use at the U's Orthopaedic Center.
|
|
|
Manage your preferences | Opt Out using TrueRemove™
Got this as a forward? Sign up to receive our future emails.
View this email online.
|
515 E 100 S, Suite 500 None | Salt Lake City, UT 84102 US
|
|
|
This email was sent to u0326349@umail.utah.edu.
To continue receiving our emails, add us to your address book.
|
|
|
|
